Report: Illumina in Talks to Acquire Cancer Diagnostics Startup Grail

It seems that Illumina (NASDAQ:ILMN) is making a push into the cancer diagnostics space. According to an article published Wednesday by Reuters citing "people familiar with the matter," the gene-sequencing specialist is in discussions to purchase Grail -- an early-stage company active in the segment.